In an interview on CNBC's Mad Money, Jagdeep Singh said QuantumScape has always been transparent about its data and about work that still needs to be done. "We're confident that the numbers we have are groundbreaking," he added. Singh noted that QuantumScape's core people have been with company for ten years and are not simply looking to make fast money. "They're a long-term committed team on a mission," he said. When asked about Scorpion Capital's allegations, he claimed that some of their points are "absurd."

In a regulatory filing, BlackRock senior managing director Mark Wiedman disclosed the sale of 1,725 common shares of the company on April 16 at a price of $812.5268 per share.

Citadel Advisors disclosed a 5.8% stake in AST SpaceMobile, which represents over 3.01M shares. The filing does not allow for activism.

The United Steelworkers said that the union has proposed returning to negotiations in-person with ATI to resolve the outstanding issues that led about 1,300 workers at nine facilities to strike over unfair labor practices on March 30, 2021. USW International Vice President David McCall, who chairs the union's negotiations with ATI, said that he hopes the overwhelming solidarity shown by the USW membership gives management an opportunity to show workers respect they have earned. "Our progress has been hindered at every step by the company dragging its feet and violating labor law," McCall said. "Now is the time for ATI to commit to resolve the outstanding issues in good faith at the bargaining table."

In a regulatory filing, Kforce disclosed that its CEO David Dunkel sold 50K shares of common stock on April 14th in a total transaction size of $2.8M, reducing his stake by about 6%.

In a regulatory filing, Carl Icahn disclosed a 13.35% stake in Tenneco, representing 10,946,841 shares. The move decreases Icahn's stake from 14.03%. The filing allows for activism.

AnPac Bio announced that it experienced strong demand for its paid tests based on the cancer differentiation analysis technology, or CDA, technology, or paid CDA-based tests, in Q1, setting a record high Q1 test volume. CDA-based tests, which are multi-cancer tests based on a novel biophysical approach, are the company's flagship product line and reached 5,439 paid cancer tests in Q1, an approximately 130% increase over the same period last year. While AnPac Bio offers multiple test products including various cancer screening tests, immunology tests and annual physical checkups, paid CDA-based tests had the highest test volume among all these tests in Q1. While the first three months of the year is traditionally a downtime due to seasonality and the Chinese New Year, the company still experienced strong demand for its commercial CDA-based tests in Q1. This increase in paid CDA-based test volume was also due to the company being negatively impacted by COVID-19 in Q1 of 2020.